Skip to main content

Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques.

Publication ,  Journal Article
Rosario, M; Borthwick, N; Stewart-Jones, GB; Mbewe-Mvula, A; Bridgeman, A; Colloca, S; Montefiori, D; McMichael, AJ; Nicosia, A; Quakkelaar, ED ...
Published in: AIDS
January 28, 2012

OBJECTIVES: Administration of synthetic long peptides (SLPs) derived from human papillomavirus to cervical cancer patients resulted in clinical benefit correlated with expansions of tumour-specific T cells. Because vaginal mucosa is an important port of entry for HIV-1, we have explored SLP for HIV-1 vaccination. Using immunogen HIVconsv derived from the conserved regions of HIV-1, we previously showed in rhesus macaques that SLP.HIVconsv delivered as a boost increased the breath of T-cell specificities elicited by single-gene vaccines. Here, we compared and characterized the use of electroporated pSG2.HIVconsv DNA (D) and imiquimod/montanide-adjuvanted SLP.HIVconsv (S) as priming vaccines for boosting with attenuated chimpanzee adenovirus ChAdV63.HIVconsv (C) and modified vaccinia virus Ankara MVA.HIVconsv (M). DESIGN: Prime-boost regimens of DDDCMS, DSSCMS and SSSCMS in rhesus macaques. METHODS: Animals' blood was analysed regularly throughout the vaccination for HIV-1-specific T-cell and antibody responses. RESULTS: We found that electroporation spares DNA dose, both SLP.HIVconsv and pSG2.HIVconsv DNA primed weakly HIVconsv-specific T cells, regimen DDDCM induced the highest frequencies of oligofunctional, proliferating CD4(+) and CD8(+) T cells, and a subsequent SLP.HIVconsv boost expanded primarily CD4(+) cells. DSS was the most efficient regimen inducing antibodies binding to regions of trimeric HIV-1 Env, which are highly conserved among the four major global clades, although no unequivocal neutralizing activity was detected. CONCLUSION: The present results encourage evaluation of the SLP.HIVconsv vaccine modality in human volunteers along the currently trialled pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines. These results are discussed in the context of the RV144 trial outcome.

Duke Scholars

Published In

AIDS

DOI

EISSN

1473-5571

Publication Date

January 28, 2012

Volume

26

Issue

3

Start / End Page

275 / 284

Location

England

Related Subject Headings

  • Virology
  • Vaccinia virus
  • Vaccines, Synthetic
  • Macaca mulatta
  • Lymphocyte Activation
  • Immunization, Secondary
  • HIV-1
  • HIV Antibodies
  • Electroporation
  • DNA, Viral
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rosario, M., Borthwick, N., Stewart-Jones, G. B., Mbewe-Mvula, A., Bridgeman, A., Colloca, S., … Hanke, T. (2012). Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS, 26(3), 275–284. https://doi.org/10.1097/QAD.0b013e32834ed9b2
Rosario, Maximillian, Nicola Borthwick, Guillaume B. Stewart-Jones, Alice Mbewe-Mvula, Anne Bridgeman, Stefano Colloca, David Montefiori, et al. “Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques.AIDS 26, no. 3 (January 28, 2012): 275–84. https://doi.org/10.1097/QAD.0b013e32834ed9b2.
Rosario M, Borthwick N, Stewart-Jones GB, Mbewe-Mvula A, Bridgeman A, Colloca S, et al. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS. 2012 Jan 28;26(3):275–84.
Rosario, Maximillian, et al. “Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques.AIDS, vol. 26, no. 3, Jan. 2012, pp. 275–84. Pubmed, doi:10.1097/QAD.0b013e32834ed9b2.
Rosario M, Borthwick N, Stewart-Jones GB, Mbewe-Mvula A, Bridgeman A, Colloca S, Montefiori D, McMichael AJ, Nicosia A, Quakkelaar ED, Drijfhout JW, Melief CJM, Hanke T. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS. 2012 Jan 28;26(3):275–284.

Published In

AIDS

DOI

EISSN

1473-5571

Publication Date

January 28, 2012

Volume

26

Issue

3

Start / End Page

275 / 284

Location

England

Related Subject Headings

  • Virology
  • Vaccinia virus
  • Vaccines, Synthetic
  • Macaca mulatta
  • Lymphocyte Activation
  • Immunization, Secondary
  • HIV-1
  • HIV Antibodies
  • Electroporation
  • DNA, Viral